NCT06239636
- Objective
- Not yet disclosed
- Design
- Not yet disclosed
- Participants
- Not yet disclosed
- Primary endpoint
- Not yet disclosed
- Results
- Results not yet reported
biotech · Breast Cancer · Pleural carcinosis · SANA
Sana Biotechnology
Sana Biotechnology is a biotech organization headquartered in Seattle, USA. It trades on NYSE under ticker SANA. Primary therapeutic focus areas include Breast Cancer, Pleural carcinosis, Parkinson’s Disease, Graves' dis
188 E Blaine St, Suite 400, Seattle, Washington 98102, US HQ
2018 Founded
265 Employees
Public company Type
SANA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 188 E Blaine St, Suite 400, Seattle, Washington 98102, US
- Founded
- 2018
- Employees
- 265
- Programs
- 19
- Drugs
- 22
- Patents
- 136
UP421
Phase 1 · mab · Type1diabetes
UP421 is a monoclonal antibody (mAb) in Phase 1 development by Sana Biotechnology for Type 1 diabetes. The program, internally designated UP421-ET1D, represents the sponsor's entry into autoimmune metabolic disease. As of December 11, 2024, the program remains active in early-stage clinical evaluation. The mechanism of
Internal code UP421-ET1D
At a glance
- Sponsor
- Sana Biotechnology
- Phase
- Phase 1
- Modality
- mab
- Indication
- Type1diabetes
- Status
- active
- Trials
- 1
Executive summary
UP421 is a monoclonal antibody (mAb) in Phase 1 development by Sana Biotechnology for Type 1 diabetes. The program, internally designated UP421-ET1D, represents the sponsor's entry into autoimmune metabolic disease. As of December 11, 2024, the program remains active in early-stage clinical evaluation. The mechanism of action, specific target, and detailed clinical rationale have not yet been disclosed. Sana Biotechnology is advancing the program independently without a disclosed partner or licensing arrangement. The company's strategy in Type 1 diabetes positions UP421 within a competitive landscape that includes other investigational approaches such as Xeris Biopharma's XeriSol glucagon, a small-molecule Phase 1 candidate. Key development milestones, regulatory pathways, and commercial projections remain undisclosed at this stage of development.
Why this program matters
Type 1 diabetes remains a significant unmet medical need despite available insulin therapies. Current standard-of-care insulin replacement does not address the underlying autoimmune destruction of pancreatic beta cells, and patients face lifelong insulin dependence, hypoglycemia risk, and complications including cardiovascular and renal disease. Monoclonal antibody therapeutics targeting immune pathways represent a mechanistic departure from insulin replacement, potentially offering disease-modifying benefits if efficacy is demonstrated.
The Type 1 diabetes therapeutic market encompasses insulin, glucagon-like peptide-1 agonists, and emerging immunomodulatory agents. A successful disease-modifying therapy could address a substantial patient population globally. Sana Biotechnology's entry into this indication via mAb technology suggests confidence in an immunological target relevant to beta-cell preservation or immune tolerance restoration.
Competitive positioning against XeriSol glucagon and other investigational agents will depend on UP421's mechanism, safety profile, and efficacy data. Early Phase 1 status indicates that differentiation, dosing strategy, and patient population definition remain to be established through clinical evidence.
Drug intelligence
Drug Class: Monoclonal antibody (mAb)
Modality: mAb
Indication: Type 1 diabetes
Sponsor: Sana Biotechnology
Mechanism of Action: Not yet disclosed
Target: Not yet disclosed
Route of Administration: Not yet disclosed
Development Status: Phase 1, active as of December 11, 2024
Related Therapies: Insulin, GLP-1 agonists, other immunomodulatory agents in development for Type 1 diabetes
Patent Status: Not yet disclosed
First Approval: Not applicable; program in Phase 1
type 1 diabetes mellitus
Also known as: IDDM, T1D, T1DM, diabetes mellitis type 1, diabetes mellitis type I, immune mediated diabetes
Overview
A chronic condition characterized by minimal or absent production of insulin by the pancreas.
Treatment landscape
ClinicalTrials.gov lists 701 registered studies for Type 1 Diabetes Mellitus (AACT aggregate).
Phase breakdown: NA (398), PHASE2 (73), PHASE1 (70), PHASE3 (51), PHASE4 (47), PHASE1/PHASE2 (38), PHASE2/PHASE3 (14), EARLY_PHASE1 (10)
Common investigational therapies:
- Placebo
- Insulin Lispro
- Insulin
- Insulin Degludec
- Sotagliflozin
- Insulin aspart
- Dapagliflozin
- Liraglutide
- Insulin glargine HOE901
- Teplizumab
Disease data sourced from MONDO Disease Ontology (MONDO:0005147), Orphanet — type 1 diabetes mellitus, NCT00021801, NCT00108004, NCT00130481, NCT00145353, NCT00145379, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Clinical development timeline
- Phase 12024-12-11
Phase 1 Active Status
UP421 remains active in Phase 1 clinical development for Type 1 diabetes.
Competitive landscape
UP421 competes within an emerging landscape of investigational Type 1 diabetes therapies. Xeris Biopharma Holdings is advancing XeriSol glucagon, a small-molecule Phase 1 candidate with a distinct mechanism from UP421's monoclonal antibody approach. XeriSol glucagon targets glucagon signaling, whereas UP421's mechanism remains undisclosed but likely targets immune pathways given its mAb modality. Both programs are in early-stage development, limiting direct clinical comparison. The competitive advantage of UP421 will depend on its target validation, safety profile, efficacy in preserving beta-cell function, and differentiation from both small-molecule and other mAb approaches in development by competitors not detailed in available facts.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| XeriSol glucagon | Xeris Biopharma Holdings | small_molecule | phase_1 |
| TEPLIZUMAB | — | T-cell surface glycoprotein CD3 epsilon chain other | Approved |
| SOTAGLIFLOZIN | — | Sodium/glucose cotransporter 1 inhibitor | Approved |
| INSULIN GLARGINE | — | Insulin receptor agonist | Approved |
| INSULIN DETEMIR | — | Insulin receptor agonist | Approved |
| DASIGLUCAGON HYDROCHLORIDE | — | Glucagon receptor agonist | Approved |
| VILDAGLIPTIN | — | Dipeptidyl peptidase IV inhibitor | Phase 3 |
| VERAPAMIL | — | Voltage-gated L-type calcium channel blocker | Phase 3 |
| TACROLIMUS ANHYDROUS | — | FK506-binding protein 1A inhibitor | Phase 3 |
| SIROLIMUS | — | FK506-binding protein 1A inhibitor | Phase 3 |
| SEMAGLUTIDE | — | Glucagon-like peptide 1 receptor agonist | Phase 3 |
| RUBOXISTAURIN | — | Protein kinase C beta inhibitor | Phase 3 |
| ROSUVASTATIN CALCIUM | — | HMG-CoA reductase inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Regulatory intelligence
FDA: Regulatory pathway and breakthrough designation status not yet disclosed.
EMA: European regulatory strategy not yet disclosed.
PMDA (Japan): Japanese regulatory engagement not yet disclosed.
NMPA (China): Chinese regulatory strategy not yet disclosed.
UP421 is in Phase 1; no filings, approvals, or label expansions have been reported. Regulatory interactions and designations remain undisclosed.
Clinical evidence summary
Key questions answered
What is UP421 used for?
UP421 is an investigational monoclonal antibody in Phase 1 development for Type 1 diabetes, designed to address the underlying autoimmune destruction of pancreatic beta cells.
Who manufactures UP421?
Sana Biotechnology is the sponsor and developer of UP421. No manufacturing partner or licensing arrangement has been disclosed.
Is UP421 approved by the FDA?
No. UP421 is in Phase 1 clinical development and has not been submitted for or approved by the FDA or any other regulatory authority.
How does UP421 work?
The mechanism of action of UP421 has not yet been disclosed by Sana Biotechnology.
What is the target of UP421?
The specific molecular target of UP421 has not yet been disclosed.
What type of drug is UP421?
UP421 is a monoclonal antibody (mAb), a type of biologic therapeutic that targets specific immune or disease-related pathways.
What clinical trial is testing UP421?
UP421 is being evaluated in clinical trial NCT06239636. Detailed trial design, objectives, and results have not yet been disclosed.
What is the current development status of UP421?
As of December 11, 2024, UP421 is active in Phase 1 development.
Does UP421 have a partner company?
No partner or licensing arrangement for UP421 has been disclosed. Sana Biotechnology is developing the program independently.
What are the competitors to UP421?
Xeris Biopharma Holdings is advancing XeriSol glucagon, a small-molecule Phase 1 candidate for Type 1 diabetes, representing a competing investigational approach with a different mechanism.
When was UP421 first disclosed?
The first disclosure date of UP421 has not been reported in available facts.
What is the route of administration for UP421?
The route of administration for UP421 has not yet been disclosed.
What is the projected peak sales for UP421?
Projected peak sales figures for UP421 have not been disclosed.
Is UP421 a breakthrough therapy?
Breakthrough therapy designation status for UP421 has not been disclosed.
What is the internal code for UP421?
The internal development code for UP421 is UP421-ET1D, where ET1D likely denotes early-stage Type 1 diabetes.
What unmet medical need does UP421 address?
UP421 addresses the unmet need for disease-modifying therapies in Type 1 diabetes that can preserve pancreatic beta-cell function and reduce insulin dependence, beyond current insulin replacement therapy.
Entity relationship graph
UP421 → Drug → Target → Indication → Company → Trials → Competitors
Analyst insights
Strategic Positioning: Sana Biotechnology's entry into Type 1 diabetes with a monoclonal antibody suggests a focus on immune tolerance or beta-cell preservation mechanisms. The undisclosed target and mechanism indicate either early-stage target validation or competitive confidentiality during Phase 1.
Development Catalysts: Key near-term catalysts include Phase 1 safety and tolerability data, target engagement biomarkers, and preliminary efficacy signals. Disclosure of the mechanism of action and target will be critical for competitive and scientific positioning.
Competitive Implications: UP421's mAb modality differentiates it from Xeris's small-molecule approach. Success will depend on demonstrating superior beta-cell preservation, immune tolerance, or safety advantages over existing therapies and competing investigational agents.
Commercial Considerations: Peak sales projections and market size estimates are not yet disclosed. Commercial viability will hinge on efficacy, safety, dosing convenience, and regulatory approval pathway. Type 1 diabetes represents a substantial market opportunity if disease modification is achieved.
Quick answers
Concise, citable answers optimized for AI answer engines.
- What is UP421?
- Investigational monoclonal antibody for Type 1 diabetes by Sana Biotechnology.
- What is the indication?
- Type 1 diabetes.
- What is the sponsor?
- Sana Biotechnology.
- What is the development phase?
- Phase 1.
- What is the modality?
- Monoclonal antibody (mAb).
- Is UP421 approved?
- No, it is in Phase 1 development.
- What is the mechanism of action?
- Not yet disclosed.
- What is the target?
- Not yet disclosed.
- Does UP421 have a partner?
- No partner disclosed.
- What is the clinical trial ID?
- NCT06239636.
- What is the route of administration?
- Not yet disclosed.
- What is the internal code?
- UP421-ET1D.
- When was the latest milestone?
- December 11, 2024.
- What is the latest milestone?
- Phase 1 active status.
- What are the competitors?
- Xeris Biopharma's XeriSol glucagon (small-molecule Phase 1).
- What is the peak sales projection?
- Not yet disclosed.
- What is the consensus position?
- Not yet disclosed.
- When was UP421 first disclosed?
- First disclosure date not reported.
- What is the expected next milestone?
- Not yet disclosed.
- Is UP421 a breakthrough therapy?
- Designation status not disclosed.
- What is the license type?
- Not applicable; no licensing arrangement disclosed.
- Who is the lead investigator?
- Not yet disclosed.
Evidence & sources
- ClinicalTrials.gov NCT06239636 (clinicaltrials)
- Source: phase (source_attribution)
- MONDO Disease Ontology (MONDO:0005147) (mondo)
- Orphanet — type 1 diabetes mellitus (orphanet)
- NCT00021801 (clinicaltrials_gov)
- NCT00108004 (clinicaltrials_gov)
- NCT00130481 (clinicaltrials_gov)
- NCT00145353 (clinicaltrials_gov)
- NCT00145379 (clinicaltrials_gov)
- AACT (ClinicalTrials.gov aggregate) (aact)
- ClinicalTrials.gov (clinicaltrials_gov)
- Open Targets Platform (opentargets)
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.